Parexel CFO, SVP Ingo Bank quits just weeks before Q4 results

CRO giant Parexel has seen its chief financial officer and senior vice president Ingo Bank resign from the company over the weekend, according to a SEC filing. 

Parexel, which is set to post its Q4/FY financial results in just over two weeks’ time (August 3), said Bank had left “in order to take a senior leadership role in another company,” without specifying where.

The Waltham, MA-based CRO said it intends quickly start looking for a permanent CFO. Bank will however continue to be an employee until mid-August, in order to help “assist in the transition of his position,” the SEC filing said.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Emma Reeve has been named interim CFO. She has been the company's corporate VP since 2014. 

Parexel said that Reeve has more than 20 years of experience in life sciences financial management, having worked as head of finance and administration for Novartis ($NVS), and has also served as biotech CFO before, notably at Inotek Pharmaceuticals.

Last October, Parexel narrowed its outlook for fiscal 2016, reducing its revenue target by about 2% at midpoint to around $2.14 billion amid sliding profits.

The CRO has also been in the process of shedding around 850 jobs during the past year, with the goal of saving between $20 million and $30 million a year starting from 2016.

- check out Parexel’s 8-K form

Related Articles:
In the midst of cuts, Parexel signs new research deal

Read more on

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.